RT info:eu-repo/semantics/article
T1 Odanacatib: a possible new therapeutic option for the treatment of osteoporosis
A1 Pérez Castrillon, José Luis
A1 Pinacho Peláez, Florentino
A1 Ruiz Mambrilla, Marta María
A1 Dueñas Laita, Antonio
K1 Osteoporosis
AB Cathepsin K is a protease released by osteoclasts, which is involved in the destruction of collagen fibers that form the organic phase of the bone matrix, and plays a key role in bone resorption. Odanacatib is a selective inhibitor of cathepsin K, which blocks bone remodeling by inhibiting resorption. Phase II trials have shown that odanacatib is a potent antiresorptive agent and does not significantly reduce biochemical markers of bone formation during long-term treatment of postmenopausal women. This increases the bone mineral density that is comparable with the most powerful antiresorptive agents. Odanacatib has a generally favorable tolerability and safety profile. Currently, only Phase II studies have been reported and its efficacy in reducing fractures has not been demonstrated. The adverse effects are reversible and disappear after discontinuation. If this antifracture efficacy can be shown, odanacatib could be a a safe, efficacious option for the treatment of osteoporosis.
PB Future Medicine
SN 1758-4272
YR 2012
FD 2012
LK http://uvadoc.uva.es/handle/10324/5879
UL http://uvadoc.uva.es/handle/10324/5879
LA eng
NO International Journal of Clinical Rheumatology, vol. 7, n. 4, p. 1-8
NO Producción Científica
DS UVaDOC
RD 17-jul-2024